Study Overview: This research examines if adding an immunotherapy drug called durvalumab to the usual chemotherapy helps treat certain types of breast cancer better. Chemotherapy involves drugs like paclitaxel, cyclophosphamide, and doxorubicin that stop cancer cells from growing. Durvalumab is an immunotherapy that boosts the immune system to fight cancer cells. The study is for patients with stage II-III hormone receptor-positive, HER2-negative breast cancer.
- Study Duration: Treatment lasts for several months, with follow-ups up to 10 years.
- Visits and Procedures: Involves regular doctor visits, blood tests, mammograms, and possibly tissue samples.
- Risks and Benefits: Potential side effects include fatigue and other chemotherapy-related symptoms. The goal is to improve survival rates and reduce cancer recurrence.
Eligibility: Participants should have specific types of breast cancer, be 18 years or older, and not have received prior treatments for their current cancer. They will need to provide tissue samples and undergo a MammaPrint test to qualify.
Considerations: Patients should discuss potential benefits and risks with their doctor to decide on participation. The study is investigational and supported by prior research suggesting improved outcomes for similar patients.